JANUX THERAPEUTICS INC (JANX)
US47103J1051 - Common Stock
Janux Therapeutics Announces Pricing of $350.0 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants
Why Janux Therapeutics Crushed the Market Today
Janux Therapeutics Announces Proposed Public Offering
Notable Tuesday Option Activity: ALK, JANX, AMKR
Janux, Vir Catapult On 'Unprecedented' Results In Prostate Cancer Patients
All 16 patients saw PSA declines of at least 50%. More than half reached a 90% decline in prostate-specific antigen levels.
JANX Crosses Below Key Moving Average Level
Oversold Conditions For Janux Therapeutics (JANX)
Janux Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights
JANX Stock Earnings: Janux Therapeutics Beats EPS, Beats Revenue for Q2 2024
JANX stock results show that Janux Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
JANX Stock Earnings: Janux Therapeutics Beats EPS, Beats Revenue for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Janux Therapeutics (NASDAQ:JANX) just reported results for the second quarter o...
Janux Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights
Commit To Purchase Janux Therapeutics At $25, Earn 17.6% Annualized Using Options
Janux Therapeutics Announces Updates to Board of Directors
Biotech Innovations Surge as Global Cancer Diagnosis Rates Continue to Climb
/CNW/ -- USA News Group – In the fight against cancer, a political stumbling block was recently put in place by the US Congress after it voted against the...
Biotech Innovations Surge as Global Cancer Diagnosis Rates Continue to Climb
/PRNewswire/ -- In the fight against cancer, a political stumbling block was recently put in place by the US Congress after it voted against the renewal of...
JANX Stock Earnings: Janux Therapeutics Beats EPS, Beats Revenue for Q1 2024
JANX stock results show that Janux Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
JANX Stock Earnings: Janux Therapeutics Beats EPS, Beats Revenue for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Janux Therapeutics (NASDAQ:JANX) just reported results for the first quarter of...
